KCM Capital Inc Invests $3.99 Million in Bristol Myers Squibb Company $BMY

Posted by Geri Gentry on Jul 23rd, 2026

KCM Capital Inc acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the first quarter, HoldingsChannel.com reports. The firm acquired 65,800 shares of the biopharmaceutical company’s stock, valued at approximately $3,991,000. Bristol Myers Squibb accounts for 0.6% of KCM Capital Inc’s investment portfolio, making the stock its 24th largest holding.

Several other institutional investors have also recently added to or reduced their stakes in the business. Northwestern Mutual Investment Management Company LLC boosted its stake in Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 172 shares during the last quarter. KCM Investment Advisors LLC increased its stake in shares of Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after acquiring an additional 174 shares during the last quarter. Investment Research Partners LLC increased its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after acquiring an additional 179 shares during the last quarter. ESG Planning DBA Harper Investing lifted its holdings in shares of Bristol Myers Squibb by 1.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after acquiring an additional 180 shares during the period. Finally, REAP Financial Group LLC boosted its position in shares of Bristol Myers Squibb by 26.1% in the fourth quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 182 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BMY. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a research note on Monday, July 6th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $61.25.

Read Our Latest Stock Report on BMY

Bristol Myers Squibb Stock Down 0.2%

Shares of NYSE:BMY opened at $60.79 on Thursday. The stock has a 50-day simple moving average of $57.29 and a 200-day simple moving average of $57.94. The stock has a market capitalization of $124.14 billion, a P/E ratio of 17.08, a PEG ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the firm posted $1.80 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.